Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Treatment Comparisons of the Retention Rate at 1 Year (ITT Population)

From: Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis

Treatment group N Retention rate, n (%) Contrasts Estimated difference (97.5% CI) Outcome
Lumiracoxib 100 mg 755 354 (46.9) Lumiracoxib 100 mg o.d. 0.02 (-0.04, 0.07) Non-inferior
o.d.    - celecoxib 200 mg o.d.   
Lumiracoxib 100 mg 1519 722 (47.5) Lumiracoxib 100 mg b.i.d. 0.02 (-0.03, 0.07) Non-inferior
b.i.d.    - celecoxib 200 mg o.d.   
Celecoxib 200 mg 758 343 (45.3)    
o.d.      
  1. CI = confidence interval; o.d. = once daily; b.i.d. = twice daily; ITT = intention-to-treat.